Lavistina

Betahistine, the active ingredient in Lavistina, is a histamine analog presented as an oral tablet for oral use. It is employed to manage vertigo and balance disorders, particularly in patients with Ménière’s disease, by improving inner‑ear blood flow.

GNH USA supplies Lavistina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution. Customers benefit from reliable supply chains, batch traceability, and responsive technical support.

Lavistina (betahistine) acts on the vestibular system to alleviate vertigo and related balance disorders. - Vertigo: reduces the frequency and intensity of spinning sensations by improving vestibular microcirculation. - Ménière’s disease: helps control episodic vertigo, tinnitus, aural fullness and hearing fluctuations through reduced endolymphatic pressure. - Balance disorders: enhances postural stability and reduces disequilibrium by increasing blood flow to the inner ear. - Dizziness: alleviates non‑vertiginous light‑headedness associated with vestibular hypofunction. - Tinnitus: may reduce the perception of ringing or buzzing sounds linked to inner‑ear pressure abnormalities.

Betahistine is generally well tolerated, but some patients may experience adverse reactions. Common Side Effects: - Headache: mild to moderate headache that may be intermittent and usually resolves without treatment. - Nausea: occasional nausea or stomach discomfort, sometimes accompanied by a feeling of queasiness. - Dyspepsia: indigestion or upper abdominal discomfort, often described as a sense of fullness after meals. - Gastric irritation: mild gastric upset, including heartburn or mild abdominal cramping. - Skin rash: transient erythematous rash that typically appears on the trunk or limbs and fades after discontinuation. Serious or Rare Side Effects: - Hypotension: unexpected drop in blood pressure that can cause dizziness or fainting, requiring medical assessment. - Allergic reaction: urticaria, swelling of the face, lips or throat, or anaphylaxis in rare cases. - Arrhythmia: irregular heart rhythm, such as palpitations or tachycardia, observed in susceptible individuals.

When using Lavistina, certain precautions should be observed to ensure safe and effective therapy. - Assess renal function: evaluate kidney status before initiating therapy, especially in elderly patients. - Monitor blood pressure: watch for signs of hypotension during treatment. - Review concomitant antihistamines: avoid concurrent use of strong H1 antagonists that may counteract effect. - Caution in asthma: consider potential bronchoconstriction in patients with reactive airway disease. - Pregnancy and lactation: use only if potential benefit justifies risk, as safety data are limited. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Betahistine may interact with other medicines; awareness of these interactions helps prevent reduced efficacy or adverse events. Major Interactions (Avoid): - Strong H1 antihistamines: may block betahistine’s H1 agonist activity, diminishing therapeutic effect. - Monoamine oxidase inhibitors (MAOIs): concurrent use can increase risk of hypertensive episodes. - CYP450 inhibitors: may alter betahistine metabolism, though clinical significance is uncertain. Moderate Interactions (Monitor Closely): - Antihypertensive agents: betahistine may enhance blood‑pressure‑lowering effects, requiring monitoring. - Diuretics: possible additive effect on blood volume and pressure. - Other vestibular suppressants: may interfere with symptom assessment and efficacy. - Anticholinergic drugs: may reduce vestibular compensation, requiring observation.